Kardigan, after raising $554m in venture capital last year, grossed $400m in the 13th biopharma IPO in the US in 2026. The proceeds will fund ongoing Phase IIb trials in cardiovascular diseases.
Kardigan, after raising $554m in venture capital last year, grossed $400m in the 13th biopharma IPO in the US in 2026. The proceeds will fund ongoing Phase IIb trials in cardiovascular diseases.